Figure 2
Figure 2. The 2-year-incidence rates (per 100 person-years) of VZV reactivation disease after HCT. Allogeneic (A) and autologous (B) HCT recipients. Acyclovir prophylaxis for VZV prevention was first introduced in 1999.

The 2-year-incidence rates (per 100 person-years) of VZV reactivation disease after HCT. Allogeneic (A) and autologous (B) HCT recipients. Acyclovir prophylaxis for VZV prevention was first introduced in 1999.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal